Table 1.
Demographic, clinical, and hematological features of COVID-19 survivors and non-survivors.
| Global Cohort (n = 119) |
Survivors (n = 90) |
Non-Survivors (n = 29) |
p-Value | |
|---|---|---|---|---|
| Age (Years) | 72 (60–81) | 68 (57–78) | 80 (74–85) | <0.001 |
| Gender (F/M) | 42/77 | 34/56 | 8/21 | 0.32 |
| Smoking Status (No/Yes/Former) | 67/36/16 | 51/27/12 | 16/9/4 | 0.99 |
| BMI (Non-Obese/Obese) | 92/27 | 68/22 | 24/5 | 0.42 |
| P/F Ratio | 278 ± 90 | 301 ± 79 | 208 ± 88 | <0.001 |
| Chest CT Severity Score | 11.0 (6.0–21.0) | 10.0 (6.0–19.5) | 15.0 (10.5–21.5) | 0.12 |
| Intensity of Care (No, OT, RSni, RSi) | 25/50/22/22 | 24/37/13/16 | 1/13/9/6 | 0.03 |
| Interval between Disease Onset and Admission (Days) | 6.5 (3.0–8.0) | 7.0 (4.0–9.0) | 4.0 (1.5–6.0) | 0.006 |
| Hospital Stay (Days) | 15 (10–26) | 20 (13–34) | 6 (4–12) | <0.001 |
| Charlson Comorbidity Index | 4.0 (2.0–7.0) | 3.5 (2.0–6.0) | 6.0 (5.0–8.0) | <0.001 |
| Cardiovascular Disease (No/Yes) | 50/69 | 44/46 | 6/23 | 0.008 |
| Respiratory Disease (No/Yes) | 93/26 | 72/18 | 21/8 | 0.39 |
| Kidney Disease (No/Yes) | 102/17 | 77/13 | 25/4 | 0.93 |
| Diabetes (No/Yes) | 94/25 | 72/18 | 22/7 | 0.64 |
| Cancer (No/Yes) | 101/18 | 76/14 | 25/4 | 0.82 |
| Autoimmunity (No/Yes) | 113/6 | 85/5 | 28/1 | 0.65 |
| ACE inhibitors (No/Yes) | 96/23 | 75/15 | 21/8 | 0.20 |
| ARBs (No/Yes) | 96/23 | 73/17 | 23/6 | 0.83 |
| WBC (×109 L) | 6.74 (5.00–9.32) | 6.47 (5.00–8.66) | 9.16 (5.65–13.52) | 0.006 |
| Monocytes (×109 L) | 0.35 (0.20–0.50) | 0.40 (0.20–0.50) | 0.30 (0.26–0.53) | 0.85 |
| Lymphocytes (×109 L) | 0.90 (0.67–1.14) | 1.00 (0.70–1.20) | 0.70 (0.60–1.03) | 0.012 |
| Neutrophils (×109 L) | 5.24 (6.30–7.58) | 5.00 (3.56–6.30) | 7.30 (3.75–11.15) | 0.012 |
| Platelets (×109 L) | 204 (162–265) | 211 (166–265) | 184 (159–259) | 0.43 |
| RDW (%) | 15.1 (14.1–16.3) | 14.9 (13.7–16.4) | 15.5 (14.8–16.1) | 0.41 |
| MPV (fL) | 8.45 (8.10–9.00) | 8.40 (8.08–8.92) | 8.60 (8.18–9.320.37) | 0.37 |
ACE: angiotensin converting enzyme; ARBs: angiotensin II receptor blockers; BMI: body mass index; COVID-19: coronavirus disease 2019; F: female; M: male; MPV, mean platelet volume; OT: oxygen therapy; RDW, red blood cell distribution width; RSi: invasive respiratory support; RSni: non-invasive respiratory support; WBC: white blood cells. All continuous variables are reported as medians and interquartile ranges. Statistical significance set at 0.05. All statistically significant values are reported in bold.